Latest news with #FosunPharma
Globe and Mail
2 days ago
- Business
- Globe and Mail
Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025
WALTHAM, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Monday, August 4, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the second quarter of 2025. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at The webcast will be archived and available for replay for 30 days following the call. About Ardelyx Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA ® (tenapanor) and XPHOZAH ® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL ® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Time Business News
16-07-2025
- Health
- Time Business News
Innovative Frontiers in Artemisinin Combination Therapy
To increase efficacy and reduce the risk of drug resistance, artemisinin combination therapy (ACT) treats malaria by mixing an artemisinin-based molecule with one or more fellow drugs. Artemisinin Combination Therapy (ACT) has expanded considerably due to high malaria burden in Southeast Asia and sub-Sahara Africa in the market due to its effectiveness against high malaria burden and drug-resistant Plasmodium Falciparum. Global health initiatives such as WHO guidelines and funding support have improved access and strength. The ongoing drug progress has also increased treatment efficacy and adherence to the patient, collectively increased market growth. Key Growth Drivers and Opportunities Urgent Demand for More Effective Malaria Treatments: A major trend that runs the future of the market is required for more effective malaria remedies between persistent cases and increasing drug resistance. It is promoting innovation in ACT formulations to develop rapid acting, long lasting, and more patient -friendly options. With increased government and international health funding, this progress is improving access and distribution in malaria-sustainable regions, the situation serves as a central solution in the global fight against malaria and promotes strong market development. Challenges Artemisinin combination therapy (ACT) faces boundaries due to the emergence of artemisinin-resistant malaria strains in the market, especially in parts of Southeast Asia. Additionally, inconsistent supply chains, high dependence on donor funding, and limited healthcare infrastructure in some spatial regions obstruct wide access. The need for constant innovation to be ahead of regulator challenges and resistance also leads to the ongoing obstacles for market stability and development. Innovation and Expansion Breakthrough A Treatment for Malaria Without Artemisinin Gives Children Hope In November 2024, Positive findings from KALUMI, a Phase 2 study of a new, non-artemisinin malaria medication combination being developed with Novartis and MMV, have been announced by the West African Network for Clinical Trials of Antimalarial Drugs (WANECAM2) consortium. Given that partial resistance to artemisinin derivatives throughout Africa jeopardizes efforts to eradicate the illness, this is a significant advancement in the fight against malaria. The effectiveness and safety of a combination of lumefantrine, reformulated for once-daily dosage, and ganaplacide, a new drug, were assessed in the KALUMI trial. This novel combination was tested against artemether-lumefantrine, the most popular artemisinin-based combination therapy (ACT) for treating uncomplicated malaria in Africa. Fosun Pharma Acquires USD 3.5M to Promote the Development of Malaria Treatments In December 2023, The Japanese Global Health Innovative Technology (GHIT) Fund has awarded Y500m (USD 3.3m) to China-based Fosun Pharma to further the development of a triple artemisinin combination medication for the treatment of malaria. Artemether, lumefantrine, and amodiaquine are the three antimalarial medications that make up the triple artemisinin combination medication, which comes in a fixed dosage format. The money used to support the Phase III research that looks into the combo treatment. Fosun, the Japanese investment firm Marubini, the Thailand-based research partnership of the universities Mahidol-Oxford Tropical Medicine Research Unit (MORU), and the product development partnership Medicines for Malaria Venture (MMV) will all work together to undertake the III trial. Novartis Provides One Billion Antimalarial Treatment Courses Globally In May 2021, Novartis declared that since 1999, it has provided one billion antimalarial therapy sessions. Over 90% of this artemisinin-based combination treatment (ACT) was given to malaria-endemic nations worldwide at no profit. The most lethal kind of malaria, P. falciparum, which accounts for more than 99% of cases in Africa and half of those in Asia, is treated with ACTs as the standard of care2. ACTs have revolutionized the treatment of malaria since the turn of the century and helped to significantly lower the number of malaria-related fatalities. Inventive Sparks, Expanding Markets Among the leading companies for artemisinin combination therapy are Novartis AG, Cipla, Bliss GVS, and KPC Pharmaceuticals, Inc. The artemisinin combination therapy (ACT) firm is focusing on developing more effective and affordable formulations, such as drug-resistant and kid-safe variants, in order to enhance treatment outcomes and accessibility. Working with governments and international health organizations is another important strategy to expand distribution in malaria-endemic areas. To ensure consistent availability, local production and supply linkages are also reinforced. These programs support global efforts to eradicate malaria, combat medication resistance, and improve patient compliance. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Yahoo
10-07-2025
- Business
- Yahoo
Teva Partners with Fosun Pharma to Advance Novel Cancer Immunotherapy TEV-56278
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the most promising stocks according to Wall Street analysts. On June 16, Teva Pharmaceutical announced a collaboration agreement with China-based Shanghai Fosun Pharmaceutical Group Co., Ltd. (better known as Fosun Pharma) to co-develop TEV-56278, which is an investigational anti-PD1-IL2 ATTENUKINE therapy. The partnership will accelerate clinical data generation for TEV-56278, which is currently in a Phase 1 study for various forms of cancer, such as melanoma. TEV-56278 is an internally developed Teva product and is an anti-PD-1 antibody-cytokine fusion protein that uses Teva's proprietary ATTENUKINE technology. A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company. Its novel mechanism of action is designed to selectively deliver interleukin-2 (IL-2) to PD-1-expressing T cells within the tumor microenvironment. Under the terms of the agreement, Fosun Pharma has been granted an exclusive license to develop, manufacture, and commercialize TEV-56278 in mainland China, the Hong Kong SAR, Macau SAR, Taiwan region, and select Southeast Asian countries. Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, manufactures, markets, and distributes generic & other medicines and biopharmaceutical products internationally. Fosun Pharma is a global healthcare company in pharmaceuticals, medical devices & diagnostics, and healthcare services. While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
09-07-2025
- Business
- Yahoo
Teva Partners with Fosun Pharma to Advance Novel Cancer Immunotherapy TEV-56278
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the most promising stocks according to Wall Street analysts. On June 16, Teva Pharmaceutical announced a collaboration agreement with China-based Shanghai Fosun Pharmaceutical Group Co., Ltd. (better known as Fosun Pharma) to co-develop TEV-56278, which is an investigational anti-PD1-IL2 ATTENUKINE therapy. The partnership will accelerate clinical data generation for TEV-56278, which is currently in a Phase 1 study for various forms of cancer, such as melanoma. TEV-56278 is an internally developed Teva product and is an anti-PD-1 antibody-cytokine fusion protein that uses Teva's proprietary ATTENUKINE technology. A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company. Its novel mechanism of action is designed to selectively deliver interleukin-2 (IL-2) to PD-1-expressing T cells within the tumor microenvironment. Under the terms of the agreement, Fosun Pharma has been granted an exclusive license to develop, manufacture, and commercialize TEV-56278 in mainland China, the Hong Kong SAR, Macau SAR, Taiwan region, and select Southeast Asian countries. Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, manufactures, markets, and distributes generic & other medicines and biopharmaceutical products internationally. Fosun Pharma is a global healthcare company in pharmaceuticals, medical devices & diagnostics, and healthcare services. While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
27-06-2025
- Business
- Yahoo
Why Nature's Sunshine (NATR) Shares Are Getting Obliterated Today
Shares of wellness products company Nature's Sunshine (NASDAQ:NATR) fell 8.5% in the afternoon session after the company announced the pricing of a secondary stock offering by a major shareholder. The offering involves major shareholder Fosun Pharma USA selling up to 2.85 million shares at a price of $12.00 per share. The stock is trading down to align with the offering price, which represents a significant discount to its previous closing price. While the company itself is not selling any new shares and will not receive any proceeds, the large block of stock hitting the market is creating selling pressure. Nature's Sunshine did note that it may buy back up to $15 million worth of shares from the offering as part of its existing repurchase program, which could help absorb some of the supply. The shares closed the day at $14.30, down 3.1% from previous close. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Nature's Sunshine? Access our full analysis report here, it's free. Nature's Sunshine's shares are quite volatile and have had 18 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 24 days ago when the stock dropped 7.2% on the news that CEO Terrence Moorehead, announced his decision to step down from his role. The board also announced the search for his successor, and Moorehead will remain in his role until a new CEO is appointed. This interim period introduced leadership uncertainty, something the market generally dislikes. Nature's Sunshine is down 4.3% since the beginning of the year, and at $13.94 per share, it is trading 20% below its 52-week high of $17.43 from November 2024. Investors who bought $1,000 worth of Nature's Sunshine's shares 5 years ago would now be looking at an investment worth $1,758. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
